UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
2009, 1, Cambridge medicine, ISBN 0521694426, xvi, 218
Book
European journal of neurology, ISSN 1351-5101, 02/2006, Volume 13, Issue 1, pp. 11 - 15
Antibodies | Therapy failure | Immunology | Botulinum toxin type B | Botulinum toxin type A | Risk factors | History, 21st Century | History, 20th Century | Humans | Risk Factors | Botulinum Toxins, Type A - immunology | Neuromuscular Agents - therapeutic use | Botulinum Toxins, Type A - history | Botulinum Toxins - immunology | Botulinum Toxins - therapeutic use | Botulinum Toxins, Type A - therapeutic use | Animals | Botulinum Toxins - history | Neuromuscular Agents - immunology | Treatment Failure | Antibody Formation | Neuromuscular Agents - history | Index Medicus
Journal Article
American journal of clinical dermatology, ISSN 1175-0561, 2010, Volume 11, Issue 3, pp. 183 - 199
Treatment | Botulinum-toxin-A | Botulinum-toxin-B | Facial-wrinkles | Therapeutic use | Botulinum-toxin | Glabellar-lines | Life Sciences & Biomedicine | Dermatology | Science & Technology | Dose-Response Relationship, Drug | Neurotoxins - pharmacology | Botulinum Toxins - therapeutic use | Esthetics | Botulinum Toxins - pharmacology | Time Factors | Cosmetic Techniques | Humans | Skin Aging - drug effects | Neurotoxins - therapeutic use | Clinical Trials as Topic | Face
Journal Article
Drugs (New York, N.Y.), ISSN 0012-6667, 09/2017, Volume 77, Issue 13, pp. 1413 - 1422
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Risk Assessment | Humans | Nervous System Diseases - drug therapy | Stroke - complications | Antibodies, Monoclonal - therapeutic use | Male | Neuromuscular Agents - therapeutic use | Stroke - drug therapy | Nervous System Diseases - complications | Botulinum Toxins, Type A - administration & dosage | Muscle Spasticity - drug therapy | Dose-Response Relationship, Drug | Motor Neurons - metabolism | Muscle Spasticity - etiology | Botulinum Toxins - therapeutic use | Botulinum Toxins, Type A - therapeutic use | Injections | Antibodies, Monoclonal - administration & dosage | Adolescent | Neuromuscular Agents - adverse effects | Neuromuscular Agents - administration & dosage | Botulinum Toxins - adverse effects | Botulinum Toxins - administration & dosage | Stroke | Complications | Botulinum toxin type A | Muscles | Spasticity | Systematic review | Injection | FDA approval | Patients | Botulinum toxin | Drug administration | Studies | Immunology | Paresis | Toxins | Drug dosages | Movement disorders | Textbooks | Pharmaceuticals
Journal Article
Journal of clinical periodontology, ISSN 0303-6979, 06/2018, Volume 45, Issue S19, pp. 396 - 396
Journal Article
2017, Intersections, ISBN 1479825263, ix, 233 pages
Book
Journal of Neural Transmission, ISSN 0300-9564, 3/2006, Volume 113, Issue 3, pp. 303 - 312
Neurology | Botulinum toxin type A, blepharospasm | Medicine & Public Health | Pharmacology/Toxicology | Psychiatry | Botulinum toxin type A | Blepharospasm | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Neuromuscular Agents - chemistry | Double-Blind Method | Humans | Middle Aged | Botulinum Toxins, Type A - chemistry | Eyelids - drug effects | Male | Treatment Outcome | Blepharospasm - drug therapy | Botulinum Toxins, Type A - administration & dosage | Hemagglutinins - adverse effects | Eyelids - physiopathology | Blepharospasm - physiopathology | Hemagglutinins - chemistry | Muscle, Skeletal - drug effects | Muscle, Skeletal - physiopathology | Neuromuscular Agents - adverse effects | Aged, 80 and over | Botulinum Toxins, Type A - chemical synthesis | Neuromuscular Agents - administration & dosage | Adult | Female | Aged | Botulinum Toxins, Type A - adverse effects | Proteins | Index Medicus
Journal Article
Cochrane database of systematic reviews, ISSN 1469-493X, 2007, Issue 3, pp. CD005493 - CD005493
Botulinum toxin type A [administration & dosage; Therapeutic use] | Neuromuscular agents [administration & dosage; Therapeutic use] | Botulinum toxins [administration & dosage; Therapeutic use] | Administration, intravesical | Botulinum Toxins - therapeutic use | Botulinum Toxins, Type A - therapeutic use | Urinary Bladder, Overactive - drug therapy | Humans | Neuromuscular Agents - administration & dosage | Adult | Neuromuscular Agents - therapeutic use | Administration, Intravesical | Botulinum Toxins - administration & dosage | Botulinum Toxins, Type A - administration & dosage | Syndrome | Randomized Controlled Trials as Topic | Index Medicus
Journal Article
Disability and rehabilitation, ISSN 0963-8288, 2007, Volume 29, Issue 23, pp. 1761 - 1768
adverse effects | antibodies | mode of action | Botulinum toxin | therapy | pharmacology | Antibodies | Therapy | Pharmacology | Adverse effects | Mode of action | Life Sciences & Biomedicine | Rehabilitation | Science & Technology | Botulinum Toxins, Type A - pharmacology | Anti-Dyskinesia Agents - therapeutic use | Botulinum Toxins - therapeutic use | Botulinum Toxins, Type A - therapeutic use | Anti-Dyskinesia Agents - pharmacology | Botulinum Toxins - pharmacology | Anti-Dyskinesia Agents - adverse effects | Humans | Muscle, Skeletal - drug effects | Neuromuscular Agents - pharmacology | Botulinum Toxins - adverse effects | Neuromuscular Agents - therapeutic use | Index Medicus
Journal Article
Journal of headache and pain, ISSN 1129-2369, 12/2014, Volume 15, Issue 1, pp. 1 - 6
Neurology | Pain Medicine | Trigeminal neuralgia | Medicine & Public Health | Botulinum toxin type A | Internal Medicine | Placebo-controlled treatment | Double-blind | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Botulinum Toxins, Type A - administration & dosage | Botulinum Toxins, Type A - pharmacology | Trigeminal Neuralgia - drug therapy | Neuromuscular Agents - adverse effects | Neuromuscular Agents - administration & dosage | Neuromuscular Agents - pharmacology | Female | Aged | Pain Measurement | Botulinum Toxins, Type A - adverse effects | Complications and side effects | Care and treatment | Neuralgia, Trigeminal | Patient outcomes | Placebos | Research | Health aspects | Botulinum toxin | Index Medicus
Journal Article
Clinical oral implants research, ISSN 0905-7161, 09/2019, Volume 30, Issue S19, pp. 343 - 343
Journal Article
Nature communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 5367 - 12
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Recombinant Proteins - metabolism | Amino Acid Sequence | Neurotoxins - chemistry | Botulinum Toxins, Type A - chemistry | Models, Molecular | Recombinant Proteins - chemistry | Crystallography, X-Ray | Neurons - cytology | Endosomes - metabolism | Neurotoxins - isolation & purification | Recombinant Proteins - isolation & purification | Sequence Alignment | Viral Envelope Proteins - chemistry | Hydrophobic and Hydrophilic Interactions | Protein Domains | Cytosol - metabolism | Liposomes - metabolism | Neurotoxins - metabolism | Botulinum Toxins, Type A - isolation & purification | Neurons - metabolism | Botulinum Toxins, Type A - metabolism | Intracellular Membranes - metabolism | Hydrogen-Ion Concentration | Molecular machines | Translocation | Self-association | Acidification | Insertion | Helices | Hydrophobicity | pH effects | Botulinum toxin | Cytosol | Neurotoxicity | Liposomes | Crystal structure | Index Medicus | BASIC BIOLOGICAL SCIENCES
Journal Article
European journal of neurology, ISSN 1351-5101, 02/2006, Volume 13, Issue 1, pp. 2 - 10
digit abduction test | diffusion | single‐fiber electromyography | botulinum toxin type A | pharmacology | Pharmacology | Diffusion | Single-fiber electromyography | Botulinum toxin type A | Digit abduction test | Neuromuscular Junction - drug effects | Humans | Poisons - pharmacology | Clinical Trials as Topic | Neuromuscular Agents - therapeutic use | Muscle Fibers, Skeletal - drug effects | Neuromuscular Diseases - drug therapy | Botulinum Toxins, Type A - pharmacology | Dose-Response Relationship, Drug | Botulinum Toxins - therapeutic use | Botulinum Toxins, Type A - therapeutic use | Botulinum Toxins - pharmacology | Animals | Drug Compounding | Neuromuscular Agents - pharmacology | Botulinum Toxins, Type A - classification | Poisons - therapeutic use | Index Medicus
Journal Article